A Phase 1a Study of IMR-687 in Healthy Adult Volunteers

Trial Profile

A Phase 1a Study of IMR-687 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs IMR 687 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Imara Inc
  • Most Recent Events

    • 17 Oct 2017 Status changed from recruiting to completed, according to Cydan media release.
    • 14 Sep 2017 According to Imara Inc media release, new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference.
    • 15 May 2017 According to Imara Inc media release, company anticipates results from this study in the summer of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top